Form 4: Immunic Inc. Executive Andreas Muehler Reports Stock Option Repricing

Andreas Muehler, Chief Medical Officer of Immunic, Inc., reports the repricing of stock options following stockholder approval.

Summary

• On March 6, 2024, Andreas Muehler, Chief Medical Officer of Immunic, Inc., filed a Form 4 with the SEC.
• The filing reports changes in beneficial ownership due to the repricing of employee stock options.
• Stockholders approved a proposal on March 4, 2024, to reduce the exercise price of eligible stock options (those with an exercise price above $3.00 per share) to the greater of $1.72 and 110% of the closing price on a future repricing date.
• The Board of Directors set the repricing date as March 4, 2024, and determined the new exercise price to be $1.72 per share.
• The Form 4 reflects the cancellation of existing eligible options and the reissuance of those options at the new exercise price of $1.72 per share.
• The original vesting schedules and expiration dates of the options remain unchanged.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a procedural change in stock option pricing. The repricing itself could be seen as a positive for employee morale, but it's not a major event.

Positives

• The repricing of stock options could incentivize employees by making the options more valuable.
• The repricing maintains the original vesting schedules and expiration dates, ensuring continued alignment with long-term company goals.

Industry Context

Stock option repricing is a common practice used by companies to incentivize employees, especially when the stock price has declined. It helps to maintain the value of the options as a form of compensation.

Stakeholder Impact

• The repricing of stock options may positively impact employees holding those options by increasing their potential value.
• Shareholders may see this as a positive move to retain and incentivize key personnel.

Key Dates